Skip to content

Medical Reference Related to Prostate Cancer

  1. Stage I Prostate Cancer Treatment

    OverviewStage I prostate cancer is defined by the American Joint Committee on Cancer's TNM classification system:[1]T1a–c, N0, M0, prostate-specific antigen (PSA) <10 ng/ml, Gleason ≤6.T2a, N0, M0, PSA <10 ng/ml, Gleason ≤6.T1–2a, N0, M0, PSA X, Gleason X.The frequency of clinically silent, nonmetastatic prostate cancer that can be found at autopsy greatly increases with age and may be as high as 50% to 60% in men aged 90 years and older. Undoubtedly, the incidental discovery of these occult cancers at prostatic surgery performed for other reasons accounts for the similar survival of men with stage I prostate cancer, compared with the normal male population, adjusted for age. Many stage I cancers are well differentiated and only focally involve the gland (T1a, N0, M0); most require no treatment other than careful follow-up.[2]In younger patients (aged 50–60 years) whose expected survival is long, treatment should be considered.[3] Radical

  2. Stage III Prostate Cancer Treatment

    OverviewStage III prostate cancer is defined by the American Joint Committee on Cancer's TNM classification system:[1]T3a–b, N0, M0, any prostate-specific antigen (PSA), any Gleason.Extraprostatic extension with microscopic bladder neck invasion (T4) is included with T3a.External-beam radiation therapy (EBRT), interstitial implantation of radioisotopes, and radical prostatectomy are used to treat stage III prostate cancer.[2] Prognosis is greatly affected by whether regional lymph nodes are evaluated and proven not to be involved. EBRT using a linear accelerator is the most common treatment for patients with stage III prostate cancer, and large series support its success in achieving local disease control and disease-free survival (DFS).[3,4] The results of radical prostatectomy in stage III patients are greatly inferior compared with results in patients with stage II cancer. Interstitial implantation of radioisotopes is

  3. Get More Information From NCI

    Sources of further information about Prostate Cancer Screening.

  4. Questions or Comments About This Summary

    If you have questions or comments about this summary,please send them to Cancer.gov through the Web site’s Contact Form. We can respond only to email messages written in English. ...

  5. Methods of Prostate Cancer Genetic Research

    Various research methods have been employed to uncover the landscape of genetic variation associated with prostate cancer. Specific methodologies inform of unique phenotypes or inheritance patterns. The sections below describe prostate cancer research utilizing various methods to highlight their role in uncovering the genetic basis of prostate cancer. In an effort to identify disease susceptibility genes, linkage studies are typically performed on high-risk extended families in which multiple cases of a particular disease have occurred. Typically, gene mutations identified through linkage analyses are rare in the population, highly penetrant in families, and have large effect sizes. The clinical role of mutations that are identified in linkage studies is a clearer one,

  6. Questions or Comments About This Summary

    If you have questions or comments about this summary,please send them to Cancer.gov through the Web site’s Contact Form. We can respond only to email messages written in English. ...

  7. General Information About Prostate Cancer

    WebMD provides an image of prostate cancer and discusses its causes and who gets it.

  8. Changes to This Summary (02 / 15 / 2013)

    The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.SignificanceUpdated statistics with estimated new cases and deaths for 2013 (cited American Cancer Society as reference 1).This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.

  9. Evidence of Benefit

    Prior to the 1990s,the digital rectal examination (DRE) was the test traditionally mentioned for prostate cancer screening. Two other test procedures are also available: transrectal ultrasound (TRUS) imaging and serum prostate-specific antigen (PSA) concentrations.[ 1 ] Prostate cancer screening is controversial because of the lack of definitive evidence of benefit. A small randomized trial in .

  10. Recurrent Prostate Cancer

    Recurrent prostate cancer is cancer that has recurred (come back) after it has been treated. The cancer may come back in the prostate or in other parts of the body. ...

Displaying 131 - 140 of 265 Articles << Prev Page 10 11 12 13 14 15 16 17 18 19 Next >>

Today on WebMD

man with doctor
Symptoms, risks, treatments
man coughing
Men shouldn’t ignore
 
prostate cancer cells
What does this diagnosis mean?
doctor and male patient
Is it worth it?
 
cancer fighting foods
SLIDESHOW
15 Cancer Symptoms Men Ignore
FEATURE
 
Prostate Enlarged
VIDEO
Picture Of The Prostate
ANATOMY
 
Prostate Cancer Quiz
QUIZ
screening tests for men
SLIDESHOW
 
Prostate Cancer Symptoms
VIDEO
Vitamin D
SLIDESHOW